NCT06238687

Who might be able to join this trial:

• Doctors expect you to live for more than 3 months.
• You have at least one area of cancer that can be measured on a scan, and it is not in an area that has been treated with radiation.
• Any side effects from your previous cancer treatments have mostly gone away (back to mild or no symptoms).
• Your blood counts and organ functions (such as liver and kidneys) are at acceptable levels (confirm with trial site).
• A heart tracing test (ECG) shows your heart's electrical activity is within a safe range.
• (For the general dose-finding part of the trial): Your cancer has come back or gotten worse after at least one standard treatment, or no standard treatment is available or suitable for you.
• (For the specific cancer group part of the trial — Cohorts A & B): You have been diagnosed with high-grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma.
• (Cohort C): You have been diagnosed with a specific type of endometrial (womb lining) cancer, it has come back or worsened after at least one course of platinum-based chemotherapy or immunotherapy, and you have had no more than 3 previous treatment courses.
• (Cohort D): You have advanced or metastatic non-small-cell lung cancer that cannot be removed by surgery, and your previous treatments meet specific requirements depending on whether you have certain genetic mutations (confirm with trial site).
• (Cohort E): You have advanced or metastatic breast cancer that cannot be removed by surgery, and your cancer tests negative for ER, PR, and HER-2 receptors (sometimes called "triple-negative breast cancer"), and you have had at least 1 but no more than 4 previous systemic cancer treatments.

Who may not be able to join:

• You have previously been treated with certain antibody-drug combinations (called ADCs) that target a specific part of cancer cells using tubulin inhibitors (confirm with trial site for specific drug names).
• You have previously received any treatment that specifically targets a protein called FolRα.
• You have had a severe allergic reaction to a monoclonal antibody therapy or a related treatment in the past.
• You have received certain cancer treatments too recently — for example, chemotherapy within the last 3 weeks, certain targeted drugs within 2 weeks, other antibody treatments within 3 weeks, or radiation or major surgery within 4 weeks (confirm with trial site for full details).
• You have a significant existing eye condition, such as corneal disease, a history of corneal transplant, uncontrolled glaucoma, macular degeneration, diabetic eye disease, cataracts causing vision problems, dry eye disease, or other serious eye conditions.
• You need to regularly take folic acid (folate) supplements, for example because of a folate deficiency.

Important: Always verify eligibility with the trial site directly before applying.